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A novel role for 14–3–3s in regulating
epithelial cell polarity
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The loss of epithelial polarity is thought to play an important role during mammary tumor progression. Using
a unique transgenic mouse model of ErbB2-induced mammary tumorigenesis, we demonstrated previously
that amplification of ErbB2 is frequently accompanied by loss of the 14–3–3s gene. Here, we demonstrate that
ectopic expression of 14–3–3s results in restoration of epithelial polarity in ErbB2-transformed mammary tumor
cells. We further demonstrate that targeted deletion of 14–3–3s within primary mammary epithelial cells
increases their proliferative capacity and adversely affects their ability to form polarized structures. Finally, we
show that 14–3–3s can specifically form complexes with Par3, a protein that is essential for the maintenance of
a polarized epithelial state. Taken together, these observations suggest that 14–3–3s plays a critical role in
retaining epithelial polarity.
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ErbB2 is a member of the epidermal growth factor re-
ceptor (EGFR) family of receptor tyrosine kinases (RTKs).
This family is comprised of four closely related type 1
RTKs: EGFR, ErbB2 (Neu, HER2), ErbB3 (HER3), and
ErbB4 (HER4) (Hynes and Stern 1994). The importance
of ErbB2 in primary human breast cancer is highlighted
by the fact that 20%–30% of human breast cancers ex-
press elevated levels of ErbB2 due to genomic amplifica-
tion of the erbB2 proto-oncogene (Slamon et al. 1987,
1989). Furthermore, its amplification and subsequent
overexpression strongly correlate with a negative clini-
cal prognosis in both lymph node-positive (Ravdin and
Chamness 1995) and lymph node-negative (Andrulis et al.
1998) breast cancer patients. In an attempt to more
closely mimic the events involved in ErbB2-induced
mammary tumor progression, we derived and character-
ized transgenic mice that carry a Cre-inducible activated
erbB2 under the transcriptional control of the endoge-
nous erbB2 promoter (herein referred to as the ErbB2KI
model) (Andrechek et al. 2000). We demonstrated that
tumor progression in this strain was further associated
with a dramatic elevation of both ErbB2 protein and
transcript levels (Andrechek et al. 2000). Remarkably,
the elevated expression of ErbB2 was further correlated
with selective genomic amplification of the activated
erbB2 allele (Montagna et al. 2002; Hodgson et al. 2005).
Comparative genome hybridization (CGH) of the erbB2
amplicon suggests that the ErbB2KI model mimics ErbB2-
initiated human breast cancer (Siegel et al. 1999).
In addition to erbB2 amplification, ErbB2KI tumors
also demonstrated frequent deletions of chromosome 4
(Montagna et al. 2002), which encompasses 30 genes in-
cluding the 14–3–3s gene (Hodgson et al. 2005). Interest-
ingly, loss of 14–3–3s expression has been noted in a large
proportion of primary human breast cancers (Ferguson
et al. 2000; Vercoutter-Edouart et al. 2001). 14–3–3s is a
putative tumor suppressor that is transactivated by p53 in
response to DNA damage (Hermeking et al. 1997). When
up-regulated, 14–3–3s induces S–G1 and G2–M cell cycle
arrests (Chan et al. 1999; Laronga et al. 2000), and blocks
Akt-mediated cell survival and proliferation (Yang et al.
2006). 14–3–3s is also involved in the cytosolic seques-
tration of EGR2, a transcription factor that is critical for
the up-regulation of erbB2 transcription (Dillon et al.
2007). Thus, ErbB2-induced tumors may ablate 14–3–3s
expression to prevent its inhibitory effects on erbB2 ex-
pression, although the role of 14–3–3s in ErbB2-induced
tumorigenesis remains unclear. Previous proteomic stud-
ies also indicate that 14–3–3s is capable of associating
with a number of polarity-regulating proteins (Benzinger
et al. 2005), as well as molecules involved in mitotic
translation machinery (Wilker et al. 2007).
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Here, we further investigated the role of 14–3–3s in
mammary epithelial biology. We directly addressed the
impact of restored 14–3–3s expression on the growth of es-
tablished ErbB2-transformed mammary tumor cell lines.
Although re-expression of 14–3–3s in these cells had
little impact on tumor cell proliferation, it significantly
decreased their invasive potential. This effect was further
correlated with the restoration of both adherent and tight
junction complexes. Conversely, inhibition of 14–3–3s
function by RNAi approaches in normal polarized epi-
thelial cells resulted in the loss of epithelial polarity. To
directly investigate the physiological relevance of these
observations, we established transgenic mice that selec-
tively delete the 14–3–3s gene in the mammary epithe-
lium. Loss of 14–3–3s function was associated with an
increase in the proliferative capacity of the mammary
epithelium, and was correlated with a loss of epithelial
polarity. We further demonstrate that 14–3–3s is able to
complex with the Par3 polarity protein. Taken together,
these observations suggest that 14–3–3s plays a critical
role in the regulation of epithelial polarity through its in-
teraction with Par3.
Results
Ectopic expression of 14–3–3s in ErbB2-transformed
mammary epithelial cells alters their metastatic
and epithelial polarity properties
To examine the impact of 14–3–3s restoration on ErbB2-
induced tumor progression, we used an established breast
cancer cell line, TM15, which is derived from mammary
tumors of the ErbB2KI mouse model, carries amplified
erbB2, and lacks 14–3–3s expression (Dillon et al. 2007,
2009). TM15 cells were infected with retroviruses and
ectopically expressing 14-3–3s, 14–3–3smut, 14–3–3z, or
the corresponding empty vector control (Supplemental
Fig. S1A). 14–3–3s mut is a truncated protein lacking
the C-terminal 40 amino acids that constitute part of
the ligand-binding domain of 14–3–3s. A mouse model
known as repeated epilation (Er) develops a skin differen-
tiation defect due to germline expression of this mutant
form of 14–3–3s (Herron et al. 2005; Li et al. 2005). We
first assessed whether expression of 14–3–3s impacted
the proliferative capacity of TM15 cells, both in vitro and
in vivo. These studies revealed that re-expression of 14–
3–3s did not alter the growth of TM15 cells compared
with empty vector controls (Supplemental Fig. S1B,C).
We next assessed whether the migratory behavior of
tumor cells was affected as a consequence of ectopic ex-
pression of 14–3–3s. We examined the motility of empty
vector control, 14–3–3s-, 14–3–3s mut-, and 14–3–3z-
expressing TM15 cells using Boyden chamber and wound
healing assays. The results revealed that elevated expres-
sion of wild-type 14–3–3s, but not the truncated 14–3–3s,
nor the closely related 14–3–3z isoform, resulted in a pro-
found impairment of epithelial migration (Fig. 1A,B). To
evaluate whether the observed migration defect was also
associated with a reduced metastatic potential, TM15
cells were injected into mammary fat pads of nude mice,
and the total tumor burden in the lungs was histologically
evaluated. In contrast to empty vector control TM15 cells
and 14–3–3z-expressing cells, the 14–3–3s-expressing
cells exhibited a dramatically impaired metastatic phe-
notype (Fig. 1C). Collectively, these data argue that res-
toration of 14–3–3s function does not impact primary
tumor growth, but significantly impairs ErbB2-induced
breast cancer metastasis.
One possible explanation for these observations is that
14–3–3s may affect the ability of tumor cells to form
adherent and tight junction complexes. To study this, we
cultured empty vector control, 14–3–3s-, 14–3–3s mut-,
and 14–3–3z-expressing cells on plastic or in collagen and
subjected them to immunostaining with E-cadherin and
Figure 1. Ectopic expression of 14–3–3s in TM15 cells alters their migratory properties. (A) Wound healing assay of TM15 cell lines
with empty vector (EV), 14–3–3s-expressing, 14–3–3smut-expressing, and HA-14–3–3z-expressing. Pictures were taken at 0, 8, 16, and
24 h after scratching. (B) In vitro migration assay of the four aforementioned TM15 cell lines using transwell chambers. Results were
normalized to TM15(EV) cells. Experiments were performed in triplicate. (C) Mammary metastatic lesions of nude mice after the
injection of TM15 cell lines into their mammary fat pads. Each cell line was injected into four nude mice. Results significantly different
from the control are indicated by asterisks: (*) P < 0.05; (**) P < 0.01.
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ZO-1 antisera as markers of adherens and tight junctions,
respectively. Remarkably, re-expression of 14–3–3s re-
sulted in the restoration of adherent and tight junction
complexes that were absent in parental cell lines on plas-
tic (Fig. 2A). In contrast, elevated expression of 14–3–3s
mut or 14–3–3z had little impact on restoration of these
cell junctional complexes. In three-dimensional (3D) col-
lagen cultures, >80% of 14–3–3s-expressing TM15 cells
had partially restored cell junctions, which were com-
pletely lost in the other cell lines expressing the other 14–
3–3 varients (Fig. 2B). Taken together, these data argue
that 14–3–3s plays a key role in assembly of these cell
junctional complexes.
Loss of 14–3–3s protein in MDCK and MCF10A cells
results in loss of epithelial polarity
To further elucidate the role of 14–3–3s in regulation of
epithelial polarity, we generated stable MDCK cell lines
that express siRNA against the endogenous canine 14–3–
3s and assessed their ability to form polarized epithelial
cysts in collagen. Stable expression of a 14–3–3s-specific
siRNA resulted in a significant loss of 14–3–3s protein
expression (Fig. 3A). While wild-type or control siRNA-
expressing MDCK cells formed hollow polarized epithe-
lial cysts with ;100% efficiency, only ;60% of MDCK
cells lacking endogenous 14–3–3s were capable of form-
ing hollow polarized cysts, while the other populations
constituted depolarized structures (Fig. 3B,C). Following
hepatocyte growth factor (HGF) stimulation, the 14–3–3s
knockdown epithelial cells also exhibited an eightfold
reduction in formation of polarized epithelial structures,
and the structures they formed were more depolarized
when compared with the controls (Fig. 3B,C). On the
other hand, under the treatment of HGF, MDCK cells
that overexpress 14–3–3s formed more hollow polarized
cysts than those MDCK cells expressing 14–3–3s mut,
14–3–3z, and empty vector control (Supplemental Fig.
S2A,B). We next investigated whether loss of 14–3–3s
would impact the ability of MCF10A mammary epithe-
lial cells to form cyst-like structures in Matrigel. Like the
MDCK cells, MCF10A cells stably expressing a siRNA
directed against 14–3–3s exhibited efficient ablation of
14–3–3s protein (Supplemental Fig. S3A). In contrast to
parental MCF10A cells and those expressing a control
siRNA, which formed hollow polarized cysts, loss of 14–
3–3s resulted in solid structures that lacked a discernable
lumen (Supplemental Fig. S3B,C). Taken together, these
observations suggest that down-regulation of 14–3–3s
results in the loss of epithelial polarity.
Generation of a conditional 14–3–3s knockout mouse
The above studies suggest that 14–3–3smay be involved
in the regulation of epithelial polarity in established epi-
thelial cell lines. In order to verify this role for 14–3–3s in
Figure 2. Ectopic expression of 14–3–3s in TM15 cells promotes cell junctions. (A) Representative immunofluorescent images of
TM15 cell lines with empty vector (EV), 14–3–3s-expressing, 14–3–3s mut-expressing, and HA-14–3–3z-expressing in monolayer
cultures. ZO-1 (green) was stained for tight junctions, and E-cadherin (red) was stained for adhesion junctions. Nuclei were
counterstained with DAPI (blue). (B) Representative immunofluorescent images of all four aforementioned TM15 cell lines in 3D
collagen cultures with the same staining. All experiments were performed in triplicate.
14–3–3s regulates epithelial cell polarity
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vivo, we decided to conditionally target the mouse 14–
3–3s gene. Given that the entire coding region of 14–3–3s
is contained within a single coding exon, we created
a targeting vector that carried the cDNA encoding 14–3–
3s flanked with LOXP recombination sites and inserted
this into the single exon, followed by a PGK-neomycin
cassette that was used for positive selection (Fig. 4A).
Embryonic stem cells carrying the conditional 14–3–3s
allele were generated andwere used to establish themouse
strain. After introgressing the conditional 14–3–3s to a
uniform FVB/N genetic background, we next interbred
this strain to a separate strain carrying the MMTV-Cre
transgene, which expresses Cre recombinase in mam-
mary epithelium, to specifically delete 14–3–3s in the lu-
minal epithelial compartment (MMTV-Cre/14–3–3sF/F).
We verified that the 14–3–3s gene was excised (Supple-
mental Fig. S4A), and its expression was lost (Fig. 4B) in
purified mammary epithelial cells from MMTV-Cre/14–
3–3sF/F animals. Notably, mice with both conditional 14–
3–3s (14–3–3sF/F) alleles also showed significantly reduced
14–3–3s levels, which may be due to the interference
of LOXP sites and/or the selection cassette on 14–3–3s
transcription (Supplemental Fig. S4B). However, no ap-
parent developmental or functional differences were ob-
served in those mice.
Disruption of 14–3–3s in mammary epithelium results
in increased epithelial proliferation and loss
of epithelial polarity
Whole-mount analyses revealed that mammary ductal
outgrowth was unaffected by 14–3–3s ablation at different
stages of mammary gland development (Supplemental Fig.
S4D). However, histological examination of virgin mam-
mary glands derived from wild-type and 14–3–3s-deficient
mice 8 wk old revealed that 14–3–3s-proficient ducts
retained a single layer of CK8+ luminal cells, while >60%
of ducts from 14–3–3s-deficient animals had multiple
layers of CK8+ luminal cells contained within a single
layer of CK14+ myoepithelial cells (Fig. 4C). Notably, the
aforementioned 14–3–3sF/F mice, which have reduced
mammary 14–3–3s levels, also exerted a similar pheno-
type (Supplemental Fig. S4C). To ascertain whether this
abnormal piling of luminal cells was due to increased
proliferation or decreased apoptosis, we performed
Ki-67 and TUNEL immunohistochemical staining. These
Figure 3. Loss of 14–3–3s in MDCK cells results in loss of epithelial polarity. (A) Immunoblot analysis to detect 14–3–3s and all 14–
3–3 protein levels in wild-type (WT), 14–3–3s–shRNA-expressing, and control shRNA-expressing MDCK cells. b-Actin was used as
loading control. (B) Representative immunofluorescent images of aforementioned MDCK cells in 3D collagen cultures, with the
exception of pictures having asterisks (*) showing the major abnormal structures. ZO-1 (green) was stained for tight junction, and
E-cadherin (red) was stained for adhesion junction. Nuclei were counterstained with DAPI (blue). (C) Percentages of hollow cyst
structures in the collagen 3D cultures of the aforementioned MDCK cells without (gray) and with (white) HGF treatment. All
experiments were performed in triplicate. Results significantly different from wild-type cells are indicated by asterisks: (*) P < 0.05; (**)
P < 0.01.
Ling et al.
950 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on October 3, 2011 - Published by genesdev.cshlp.orgDownloaded from 
analyses revealed that the rate of apoptotic cell death was
unaffected in 14–3–3s-deficient glands (Fig. 4D). Instead,
the 14–3–3s-deficient cells exhibited a threefold increase
in their proliferative capacity (Fig. 4D). These data argue
that multilayer epithelial structures observed in the 14–
3–3s-deficient glands result from increased proliferation
of the luminal epithelial cell population.
Disruption of 14–3–3s in mammary epithelium results
in down-regulation of cell junctions and loss
of epithelial polarity
To investigate whether the multilayer epithelial pheno-
type observed in the 14–3–3s-deficient gland is related
to loss of epithelial polarity, we plated isolated mam-
mary epithelial cells from control and 14–3–3s-deficient
mice on transwells and stained them with ZO-1 and
E-Cadherin antibodies. In contrast to control cells, 14–3–
3s-deficient epithelial cell junctions were disrupted at
both the basal and apical layers (Fig. 5A,B). Subsequently,
we placed the cells in 3DMatrigel cultures. In contrast to
the highly polarized acini derived from control cells, the
14–3–3s-deficient epithelial cells formed structures that
had filled lumens with depolarized epithelial growth (Fig.
5C). Careful quantification of the number of polarized
structures revealed that the percentage of polarized cysts
was reduced dramatically compared with wild-type con-
trols (Fig. 5D).
One possible explanation for the ability of 14–3–3s to
modulate epithelial polarity is through its interactionwith
components of the polarity (Par) complex. Indeed, the reg-
ulation of phosphorylation of key serine residues in Par3
that regulate binding of 14–3–3 proteins has been proposed
recently as an important modulator of epithelial polarity
(Hurd et al. 2003). To explore this possibility, we performed
coimmunoprecipitation studies inMDCK cells to evaluate
whether 14–3–3s could interact with Par3. The results
showed that Par3 could be detected readily in physical
complexes with 14–3–3s, but not with the truncated 14–
3–3s mutant (Fig. 6A). Immunofluoresent staining of
MDCK cells showed colocalization of 14–3–3s and Par3
at the membrane, while corresponding 14–3–3s-deficient
cells displayed lower Par3 levels at themembrane (Fig. 6B).
The same phenomenon was also observed in the 3D
Matrigel cultures of 14–3–3s-deficient mammary epithe-
lial cells, when comparedwith controls (Fig. 6C). Together,
these observations suggest that 14–3–3s canmodulate epi-
thelial polarity through its specific association with Par3.
Figure 4. Targeted disruption of 14–3–3s results in abnormal mammary epithelial development. (A) Schematic depicting the 14–3–3s
locus, the targeting construct, the targeted allele, and the excised allele. The Southern probe used for screening is indicated. (H) HindIII;
(E) EcoRI; (X) XhoI; (C) ClaI; (S) SpeI. (B) Immunoblot analysis to detect 14–3–3s and all 14–3–3 protein levels in the mammary gland
protein extracts from mice of indicated genotypes. b-Actin was used as loading control. (C) Representative H&E and immunohisto-
fluorescent stainings of mammary gland paraffin sections from 8-wk-old wild-type and conditional 14–3–3s virgin mice, three for each
strain. CK8 (green) was stained for luminal epithelium, and CK14 (red) was stained for myoepithelium. Nuclei were counterstained
with DAPI (blue). (D) Percentages of positively Ki67-stained (gray) and TUNEL-stained (white) cells in the epithelium of
aforementioned mouse mammary gland paraffin sections. All experiments were performed in triplicate. Results significantly different
from wild-type cells are indicated by asterisks: (*) P < 0.05; (**) P < 0.01.
14–3–3s regulates epithelial cell polarity
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Discussion
The pathogenesis of breast cancer is thought to involve
multiple genetic events. Karyotypic and epidemiological
analyses of mammary tumors at various stages suggest
that breast carcinomas become increasingly aggressive
through the stepwise accumulation of genetic changes.
The majority of genetic changes found in human breast
cancer fall into two categories: gain-of-function muta-
tions in proto-oncogenes involved in supporting cell
growth, division, and survival; and loss-of-function mu-
tations in so-called tumor suppressor genes involved in
preventing unrestrained cellular growth. Genetic and bio-
chemical analyses of ErbB2-induced mammary tumors
have revealed that amplification of ErbB2 involves coam-
plification and coexpression of several closely linked
genes, including Grb7 (Siegel et al. 1999; Kauraniemi
et al. 2001; Montagna et al. 2002; Andrechek et al. 2003).
In addition to the elevated expression of these compo-
nents of the erbB2 amplicon, the loss of a region of mouse
chromosome 4 spanning the 14–3–3s tumor suppressor is
frequently observed in mouse models of ErbB2 tumor
progression (Dillon et al. 2007). Consistent with these
observations, 90% of mammary tumors that arise in the
ErbB2KI transgenic mouse model fail to express the 14–3–
3s protein (Montagna et al. 2002). In human breast
cancers, loss of 14–3–3s expression is also frequently
observed (Andrechek et al. 2003), and involves the de-
letion of the distal end of chromosome 1p, which is
syntenic with mouse chromosome 4 (Genuardi et al.
1989; Tsukamoto et al. 1998). Whereas these genetic stud-
ies suggest that the loss of 14–3–3s is a common event in
ErbB2-induced mammary tumor progression, its role in
this process is poorly understood. Here, we demonstrate
that the loss of 14–3–3s plays a critical role in positively
regulating epithelial polarity.
ErbB2 tumor cells engineered to re-express 14–3–3s
indicate that this protein can suppress several key fea-
tures of ErbB2-induced tumor progression. Specifically,
we demonstrated that, while restoration of functional 14–
3–3s had little impact on in vitro and in vivo growth
properties of these tumor cells (Supplemental Fig. S1B,C),
these tumor cells had impaired migratory behavior that
was further correlated with dramatic reduction in their
metastatic capacity (Fig. 1C). The impairment of the
metastatic phenotype by re-expression of 14–3–3s was
Figure 5. Primary mammary epithelial cells lacking 14–3–3s have lost epithelial polarity. (A) Representative immunofluorescent
images of control mammary epithelial cells (MMTV-Cre/14–3–3s+/+) and 14–3–3s-deleted cells (MMTV-Cre/14–3–3sF/F) in transwell
monolayer cultures. ZO-1 (green) was stained for tight junctions, E-Cadherin (red) was stained for adhesion junctions. Nuclei were
counterstained with DAPI (blue). (B) Quantification of polarized and nonpolarized epithelial cells. The ability of the cells to localize
ZO-1 to the apical–lateral border was analyzed using XZ optical sections. A total of 189 out of 252 control cells (MMTV-Cre/14–3–3s+/+)
and 28 out of 259 14–3–3s-deleted cells (MMTV-Cre/14–3–3sF/F) were classified as polarized. (C) Representative immunofluorescent
images of those mammary cells in 3D Matrigel cultures with the same staining. (D) Percentages of hollow cyst structures of those cells
in the 3D Matrigel cultures. Results significantly different from control cells are indicated by asterisks: (*) P < 0.05; (**) P < 0.01. All
experiments were performed in triplicate.
Ling et al.
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further correlatedwith restoration of both tight junctional
and adherens complexes (Fig. 2A,B). Previous studies
have suggested that elevated expression of 14–3–3s may
impact cell cycle progression in certain cancer cell lines
(Hermeking et al. 1997; Laronga et al. 2000). The observed
lack of an effect of re-expression of 14–3–3s on cell pro-
liferation in TM15 tumor cell lines may reflect the loss of
checkpoint controls in these cells. However, the dramatic
impact on re-expression of 14–3–3s on impairing meta-
static progression (Fig. 1C) indicates that 14–3–3s may
target other steps in tumor progression. The observation
that loss of 14–3–3s is a frequent event in a number of
ErbB2mammary tumormodels and primary human breast
cancers (Ferguson et al. 2000; Vercoutter-Edouart et al.
2001) is consistent with the notion that loss of 14–3–3s is
a rate-limiting step in ErbB2-induced tumor induction.
Consistent with the importance of 14–3–3s in ErbB2-
driven tumor induction, loss of 14–3–3s in MDCK and
MCF10A epithelial cells resulted in a dramatic disruption
of epithelial polarity (Fig. 3C; Supplemental Fig. S3C).
Remarkably, the disorganized structures that are formed
through down-regulation of 14–3–3s closely resemble the
structures that are formed by these cells upon induction
of ErbB2 expression (Muthuswamy et al. 2001; Khoury
et al. 2005). More recently, this ErbB2-dependent disrup-
tion of epithelial polarity has been linked to the interac-
tion of the Par6/aPKC complex with ErbB2 (Aranda et al.
2006). The capacity of 14–3–3s to restore epithelial polar-
ity in ErbB2-expressing tumor cells (Fig. 2A,B) suggests
that it can override ErbB2-dependent signals. The observed
capacity of 14–3–3s to complex with Par3 (Fig. 6A) may be
partly responsible for this effect. Indeed, the modulation of
epithelial polarity by interaction of 14–3–3 proteins has
been noted previously in several different epithelial cell
types (Benton and Johnston 2003; Hurd et al. 2003).
The concept that 14–3–3s plays an instrumental role in
the regulation of epithelial polarity in vivo is supported
by the mammary epithelial disruption of this key tumor
suppressor. Although mammary epithelial-specific dis-
ruption of 14–3–3s had little impact on the initial stages
of ductal outgrowth (Supplemental Fig. S4D), histological
analysis of 14–3–3s-deficient epithelium revealed an in-
crease in the number of luminal epithelial cells that
correlated with an increase in the proliferative capacity
of these cells (Fig. 4D). Furthermore, in contrast to well-
organized single-layer epithelial organoids derived from
wild-type mammary epithelium, the 14–3–3s-deficient
organoids were filled structures that bore a remarkable
similarity to mammary organoids that ectopically ex-
press ErbB2. Consistent with the importance of 14–3–3s
in controlling polarity of luminal mammary epithelium,
the mammary glands derived from the hypomorphic
conditional 14–3–3s strain (Fig. 4B; Supplemental Fig.
S4B) exhibited an identical luminal hyperproliferation
Figure 6. Association of 14–3–3s and epithelial polarity protein Par3. (A) Coimmunoprecipitations of V5-14–3–3s and HA-Par3
proteins in MDCK cells, with secondary antibody precipitations and straight cell lysates as controls. (B) Representative immunoflu-
orescent images of MDCK cells with control shRNA and 14–3–3s shRNA in monolayer cultures. 14–3-–3s was stained green. Par3 was
stained red. Nuclei were counterstained with DAPI (blue). Both yellow and white arrows indicate cell membranes. (C) Representative
immunofluorescent images of mammary epithelial cells (MMTV-Cre/14–3–3s+/+) and 14–3–3s-deleted cells (MMTV-Cre/14–3–3sF/F) in
3D Matrigel cultures with the same staining. All experiments were performed in triplicate.
14–3–3s regulates epithelial cell polarity
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phenotype (Supplemental Fig. S4C), suggesting that a crit-
ical threshold of 14–3–3s is required to restrict luminal
epithelial proliferation.
While the precisemechanisms thatmodulate epithelial
polarity are unclear, proteomic analyses have revealed that
14–3–3s can interact with several proteins that play im-
portant roles in regulating cell contacts (Benzinger et al.
2005). Indeed, we showed that 14–3–3s interacts with the
Par3 component of the polarity complex, although the
association with Par3 might not be direct. Loss of 14–3–3s
leads to dislocation of Par3 from cell membranes, while it
has little impact on Par3 protein levels in TM15, mouse
primary mammary epithelium, or MDCK cells (Supple-
mental Figs. S1A, S5A,B). Previous studies in Drosophila
have indicated that 14–3–3 protein plays a crucial role in
establishing epithelial polarity through its action on Par3
function (Benton and Johnston 2003). There is also recent
evidence to suggest that Par3 plays a crucial function in
regulating mammary epithelial biology. Disruption of
Par3 in the mammary epithelium results in mammary
epithelial hyperplasia with luminal filling (McCaffrey and
Macara 2009). Further evidence supporting the role of 14–
3–3s in epithelial polarity derives from studies of a mouse
mutant bearing a truncated 14–3–3s protein. Mice hetero-
zygous for this truncated 14–3–3s gene have disrupted
epithelial stratification in the skin, and homozygous
fetuses die shortly after birthwith severe skin abnormality
(Herron et al. 2005; Li et al. 2005). In addition, primary
corneal epithelial cells expressing this dominant-negative
protein failed to differentiate and form tight junctions (Xin
et al. 2010). Taken together with our observations, these
data suggest that 14–3–3s plays a critical role in regulating
epithelial polarity. In contrast to the positive effects of 14–
3–3s on epithelial polarity, ectopic expression of 14–3–3z
results in disruption of epithelial polarity of MDCK cells
through binding Par3 (Hurd et al. 2003). Moreover, ele-
vated expression of 14–3–3z can enhance the invasiveness
of mammary tumor cell lines (Fig. 1C; Lu et al. 2009). It is
conceivable that the opposing effects on epithelial polarity
of these two closely related 14–3–3 proteins is due to their
ability to localize Par3 to distinct apical and basal com-
partments within the cell.
The observation that ErbB2 tumors are associated with
loss of 14–3–3s has important implications in under-
standing the genetic events involved in ErbB2-induced
tumor progression. The fact that 14–3–3s is a major
positive regulator of epithelial polarity suggests that loss
of polaritymay be an important step in tumorigenesis and
metastasis. Consistent with this concept, it has been
demonstrated recently that loss of the Scribble polarity
regulator plays an important role in c-Myc-induced
mammary tumors (Zhan et al. 2008). Whether 14–3–3s
plays a comparable role in ErbB2 mammary tumor pro-
gression remains to be addressed.
Materials and methods
Plasmid constructs
14–3–3s cDNA, 14-3-3smut cDNA, V5-tagged 14–3–3s cDNA,
and V5-tagged 14–3–3smut cDNAwere cloned into EcoRI/XhoI
sites of pcDNA3 (Invitrogen), and 14–3–3s cDNA and 14-3-3s
mut cDNA were subsequently cloned into BglII/HpaI sites of
pMSCVhygro (Clontech). The primer sequences used were SfnF,
59-CGGAATTCATGGAGAGAGCCAGTCTGATC-39; V5SfnF,
59-CCCAAGCTTATGGGTAAGCCTATCCCTAACCCTCTCC
TCGGTCTCGATTCTACGGGATCCATGGAGAGAGCCAGT
CTGATC-39; SfnR, 59-CCGCTCGAGTCAGCTCTGGGGCTC
CTCCG-39; SfnMR, 59-CCGCTCGAGTCACTGAAGGGTGTG
CAGGTCGG-39. shRNA oligo pairs specific to canine and hu-
man 14–3–3s and control shRNA pairs were inserted into the
HindIII/BglII sites of pSUPER.retro.puro (OligoEngine). The primer
sequences used were SfnDF, 59-GATCCCCTTGAGGAGTGTC
CCACCCTTTCAAGAGAAGGGTGGGACACTCCTCAATTT
TTGGAAA-39; SfnDR, 59-AGCTTTTCCAAAAAGTGACCCT
GTTTCCTCTCATCTCTTGAATGAGAGGAAACAGGGTCAC
GGG-39; SfnHF, 59-GATCCCCGTGACCATGTTTCCTCTCAT
TCAAGAGATGAGAGGAAACATGGTCACTTTTTGGAAA-39;
SfnHR, 59-AGCTTTTCCAAAAAGTGACCATGTTTCCTCTC
ATCTCTTGAATGAGAGGAAACATGGTCACGGG-39; SfnCF,
59-GATCCCCGAGTAGGAGAGATATAGAGTTCAAGAGAC
TCTGTGTCTCTCCTGCTCTTTTTGGAAA-39; SfnCR, 59-AG
CTTTTCCAAAAAGAGTAGGAGAGATATAGAGTCTCTTG
AACTCTGTGTCTCTCCTGCTCGGG-39.
Conditional knockout of 14–3–3s
The 14–3–3s locus was isolated by screening the Lambda FIX II
Library (Stratagene) by PCR. A 6-kb EcoRI–SpeI fragment con-
taining the only 14–3–3s exon was cloned into the pGem-9Zf
vector (Promega), and was used to build the targeting construct.
A cDNA encoding mouse 14–3–3s was obtained by RT–PCR.
The PCR product with a 59 loxP site was followed by SV40 PolyA
signal with a downstream loxP site, and followed by a PGK-
neomycine selection cassette (Invitrogen). The whole 2.9-kb
XhoI–ClaI fragment was used to replace the corresponding part
of the exon, which included the first 434 coding base pairs. The
primer sequences used for targeting construct were LoxSfnF,
59-CCGCTCGAGATAACTTCGTATAGCATACATTATACGA
GGTTATACAGCCAGTTCGCCCGTC-39; SfnR, 59-CCCAAG
CTTGCTGCTTCAGCTCTGGGGC-39; PolyAF, 59-CCCAAGC
TTGGGTTCGAAATGACCGACC-39; LoxPolyAR, 59-GAAGA
TCTATAACTTCGTATAATGTATGCTATACGAAGTTATAAG
CTCTAGCTAGAGGTCG-39; NeoF, 59-CCATCGATGAAGTTC
CTATACTTTCTAGAGAATAGGAACTTCGAATTCTACC-39;
NeoR, 59-GAAGATCTGAAGTTCCTATTCTCTAGAAAGTAT
AGGAACTTCAAGCTCTAGCTAGAGGTCG-39. The vector
was linearized with NotI, and gene targeting was performed
following standard techniques using the embryonic stem cell
line R1. Embryonic stem cell clones containing the correct inte-
gration event were identified by Southern blotting with a 59 ex-
ternal probe. The primer sequences used were ProbeF, 59-TTCAT
CTTGCCATTGCCTGG-39; ProbeR, 59-TCAACAGTCTGAC
CAGAGGG-39. Two embryonic stem cell clones were then used
to generate chimeras and subsequent lines of mice heterozygous
for 14–3–3s (14–3–3sF/+) by the McGill Transgenic Facility. The
mice were introgressed in a FVB/N background. 14–3–3sF/+
animals were interbred with the MMTV-Cre transgenic to gen-
erate MMTV-Cre/14–3–3sF/F mice, which have a mammary-
specific 14–3–3s knockout.
Cell lines
MDCK cells were maintained in DMEM (Invitrogen) supple-
mented with 10% fetal bovine serum (Wisent). TM15 cells were
maintained in DMEM with 10% fetal bovine serum with MEGS
supplements (Cascade Biologics). Cell lines were generated by
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retroviral infection, followed by 2 mg/mL and 4 mg/mL puromy-
cine selection for MDCK and TM15, respectively. Primary
mammary epithelial cells were obtained from virgin mouse
mammary glands. Mammary glands were harvested and pro-
cessed with the McILWAN Tissue Chopper, and were disasso-
ciated in DMEM with 2.4 mg/mL Collagenase B (Roche) and 2.4
mg/mL Dispase II (Roche) for 3 h at 37°C. Disassociated cells
were washed with PBS/EDTA (1 mM), plated on plastic, and
maintained in DMEM with 2% fetal bovine serum with MEGS
supplements.
3D cell culture
For 3D collagen cultures, 24-well plates (NUNC) were used. For
each well, 350 mL of 80% collagen I (Inamed) in PBS (pH 7.4) was
plated and solidified for 45 min at 37°C without CO2. Sub-
sequently, 3000 monodispersed cells mixed with 500 mL of
collagen were seeded on top and incubated for 30 min at 37°C
without CO2. One milliliter of Leibovitz’s L-15 medium (Invi-
trogen) was applied into each well and changed every 4 d. For
HGF stimulation, after 12 d of culture, HGF (gift from Dr. Morag
Park) was added in the medium to a final concentration of
10 U/mL, and cells were cultured with HGF for an additional
2 d before subsequent staining. For 3D Matrigel cultures, eight-
well Chamber slides (NUNC) were used. For each well, 100 mL
of Matrigel (BD Biosciences) was plated and solidified for 30 min
at 37°C. Later, 1500 monodispersed cells mixed in 300 mL of
DMEM with 2% fetal bovine serum (BSA), 2% Matrigel, and
MEGS supplements were seeded on top. Medium was changed
every 4 d. Cells were stained after 10 d of culture.
Immunoblotting
For immunoblotting, membranes were blocked in TBS with 3%
skim milk, and incubated overnight with primary antibodies in
3% skim milk: 14–3–3s (1:1000; Santa Cruz Biotechnologies);
14–3–3pan (1: 1000; Millipore); b-actin (1:5000; Sigma); HA-11
(1:5000; Covance); and Par3 (1:1000; Millipore). Later, mem-
branes were treated by 1 h of incubation at room temperature
with HRP-conjugated mouse, rabbit, and goat secondary anti-
bodies (1:5000 in TBS/3%milk; Jackson Laboratories). Blots were
developed with enhanced chemiluminescence (Amersham).
Immunofluorescence (IF)
Cells were fixed for 15 min at room temperature with 2%
paraformaldehyde in PBS, permeabilized for 10 min in 0.5%
Triton X-100 in PBS, followed by washes of 100 mM glycine in
PBS. Blocking was performed with IF buffer (PBS, 0.1% BSA,
0.2% Triton X-100, 0.05% Tween-20) plus 2% BSA for 1 h
followed by 1 h of incubation at room temperature with the
following primary antibodies diluted in IF buffer: Par3 (1:100;
Millipore); 14–3–3s (1:100; Millipore); E-Cadherin (1:100; BD
Transduction Laboratories); and ZO-1 (1:100; Zymed). Cells were
washed in IF buffer and incubated in a humidified chamber with
the appropriate Alexa-fluor-conjugated secondary antibodies
(1:1000; Molecular Probes) diluted in IF buffer for 45 min at
room temperature. The nuclei were counterstained with 49,6-
diamidino-2-phenylindole (DAPI) (Jackson Laboratories) for 5min.
Immunohistofluorescence (IHF)/immunohistochemistry
(IHC)
Paraffin-embedded sections were deparaffinized in three changes
of xylenes. Sections were heated in 10 mM sodium citrate (pH 6),
followed by incubation in 3% H2O2 for 20 min. Samples were
incubated in primary antibodies of CK8, CK14 (1:100; Covance),
and Ki67 (1:100; Cedarlane) diluted in PBS/2% BSA for 1 h at
room temperature. For IHF, samples were incubated in a humid-
ified chamber with the appropriate Alexa-fluor-conjugated sec-
ondary antibodies (1:1000; Molecular Probes) diluted in IF buffer
for 45 min at room temperature, followed by nuclei counter-
staining with DAPI for 5 min. For IHC, samples were subject to
incubation at room temperature with HRP-conjugated second-
ary antibody (1:1000 in PBS/2% BSA; Jackson Laboratories).
Immunoreactivity was visualized using the DAB+ substrate
chromagen system (DAKO), and the tissues were counterstained
with hematoxylin. For TUNEL IHC staining, the ApopTag Fluo-
rescein in Situ Apoptosis Detection Kit (Serological) was used.
Coimmunoprecipitation
Forty-eight hours after transient transfection of MDCK cells
with pcDNA3-V5-14–3–3s, pcDNA3-V5-14–3–3smut, and pKH3-
Par3 using Fugene6 (Roche), cells were lysed with modified
TNE buffer supplemented with protease inhibitors and Na3VO4.
Immunoprecipitations were performed overnight at 4°C
with antibodies to V5 tag (1:150; Genway) and HA tag (1:150;
Covance). Immunoprecipitations were then incubated for 2 h
with protein G-agarose (Amersham Biosciences). The reaction
products were washed with lysis buffer, and the immune com-
plexes were resolved by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE). The proteins were electrotrans-
ferred to polyvinylidene difluoride membranes, and the mem-
branes were immunoblotted with antibodies to Par3 (1:1000;
Millipore), and 14–3–3s (1:1000; Santa Cruz Biotechnologies),
followed by secondary antibody incubation and subsequent de-
veloped with enhanced chemiluminescence (Amersham).
Confocal imaging
Confocal imaging was performed using an Axiovert 200M
microscope (Carl Zeiss MicroImaging, Inc.) with 403, 633, and
1003/1.4 plan-APOCHROMAT objectives equipped with a con-
focal microscope system (LSM 510 Meta confocal microscope;
Carl Zeiss MicroImaging, Inc.). Image analysis was carried out
using the LSM 5 image browser (Empix Imaging).
Statistics
Statistically significant differences were determined using the
Student’s t-test. Differences were considered significant if P <
0.05, and dramatically significant if P < 0.01.
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